| Market Cap | ₹1,12,084 CrLarge Cap |
|---|---|
| PE TTM | 24.84Sector PE 44.82 |
| Promoter Holding | 75.01%Stable QoQ |
| RSI | 42.73Neutral Zone |
Key highlights
- Final USFDA approval received for Estradiol and Levonorgestrel Transdermal System (0.045 mg/0.015 mg per day)
- Designated as a Competitive Generic Therapy (CGT) with 180-day market exclusivity
- Targeting a US market with annual reference product sales of approximately USD 45.7 million
- Manufacturing to take place at the group's Moraiya facility near Ahmedabad, Gujarat
- Zydus portfolio grows to 458 total USFDA approvals with 516 ANDAs filed as of September 2026
Strategic Entry into USD 45.7 Million US Market
Zydus Lifesciences Limited has reached a significant regulatory milestone with the USFDA's final approval of its Abbreviated New Drug Application for the Estradiol and Levonorgestrel Transdermal System. This product is primarily indicated for the treatment of moderate to severe menopause symptoms and the prevention of osteoporosis in postmenopausal women. The reference drug, Climara Pro, recorded annual sales of approximately USD 45.7 million in the United States according to IQVIA MAT August 2026 data.
By securing the Competitive Generic Therapy designation, Zydus is eligible for 180 days of shared or sole exclusivity, providing a competitive advantage during the initial commercial marketing phase.
Manufacturing at Moraiya and Financial Context
The newly approved transdermal system will be manufactured at the company’s dedicated facility in Moraiya, Ahmedabad. This approval adds to a robust pipeline; as of September 30, 2026, the group has secured 458 approvals and filed over 516 ANDAs. For the quarter ended June 30, 2026, Zydus reported operating revenue of ₹8,017 crore, representing a 22% year-on-year growth, though net profit for the same period stood at ₹939.8 crore, a decline of 35.9% compared to the previous year.
The company maintains an operating profit margin of 24.1%, aligning with its long-term management guidance for operational profitability.
Expanding Regulatory Track Record in 2026
- August 21, 2026: Received USFDA approval for Ascorbic Acid Injection with 180-day CGT exclusivity
- August 04, 2026: Secured final approval for Indocyanine Green for Injection with 180-day CGT exclusivity
- April 08, 2026: Granted approval for Dapagliflozin Tablets with 180-day shared generic exclusivity
- March 14, 2026: Received marketing approval from China's NMPA for the novel drug Desidustat
- March 13, 2026: Obtained final USFDA approval for Cevimeline Hydrochloride Capsules
- February 18, 2026: Approved for Bosentan Tablets for Oral Suspension by the USFDA
| Date | Announcement | Amount |
|---|---|---|
| 21 Aug 2026 | Final approval received from USFDA for Ascorbic Acid Injection USP (25,000 mg/50 mL and 5,000 mg/10 mL) with 180-day CGT exclusivitySource: pharmabiz.com | – |
| 04 Aug 2026 | Final approval received from USFDA for Indocyanine Green for Injection USP (25 mg/vial) with 180-day CGT exclusivitySource: zyduslife.com | – |
| 08 Apr 2026 | Final approval received from USFDA for Dapagliflozin Tablets (5 mg and 10 mg) with 180-day shared generic exclusivitySource: zyduslife.com | – |
| 14 Mar 2026 | Marketing approval received from China's NMPA for novel drug Desidustat (licensed to China Medical System Holdings)Source: market data.com | – |
| 13 Mar 2026 | Final approval received from USFDA for Cevimeline Hydrochloride Capsules (30 mg)Source: market data.com | – |
| 18 Feb 2026 | Final approval received from USFDA for Bosentan Tablets for Oral Suspension (32 mg)Source: zyduslife.com | – |
What to watch next
- Board meeting scheduled for November 04, 2026, to approve Q2 financial results
- USFDA review decision for Keytruda biosimilar FYB206 expected by Q3 2027
| Share price | ₹1113.9 |
|---|---|
| Market capitalisation | ₹1.12L Cr |
| Revenue (annual) | ₹27,148.40 Cr |
| Net profit (annual) | ₹5,040.00 Cr |
| Revenue (latest quarter) | ₹8,017.00 Cr+5.67% vs previous quarter |
| Net profit (latest quarter) | ₹939.80 Cr-26.15% vs previous quarter |
| P/E (TTM) | 24.84×Sector 44.82× |
| Promoter holding | 75.01%0.00% QoQ |
| FII holding | 7.05%Current quarter |
Reference market data from a third-party provider, as of the story. Not a valuation or a recommendation.
Exchange filing by Zydus Lifesciences Limited announcing the final USFDA approval for Estradiol and Levonorgestrel Transdermal System. Market figures from a third-party data provider.
Track Zydus Lifesciences live
Get the next Zydus Lifesciences filing on Telegram seconds after it lands. 15 days free.
